What does HC Pharma do?

HC Pharma is a pharmacy in Hamme (Vl.). Private Limited, started on 14 April 1961, 1 establishment.

What is the address of HC Pharma?

The registered office of HC Pharma is located at Kapellestraat 55, 9220 Hamme (Vl.).

Is HC Pharma still active?

Yes. According to the CBE (29 October 2026) HC Pharma is active, legal situation “Normale toestand”, started on 14 April 1961.

Is HC Pharma registered on Peppol?

Yes, HC Pharma is registered on the Peppol network with ID 0208:0405023993.

What is the enterprise number of HC Pharma?

The enterprise number of HC Pharma is BE0405023993.

When was HC Pharma founded?

HC Pharma was founded on 14 April 1961.

Who are the directors of HC Pharma?

According to the 2025 annual accounts, the directors of HC Pharma are: Sodiap BV, Alexo BV, Louwagie Consulting BV.

Is HC Pharma a reliable company?

Databakkes does not pass judgement; this is what the sources say: Active according to the CBE since 14 April 1961; 5 annual accounts filed, latest fiscal year 2025; 3 directors known from the annual account.

How much profit did HC Pharma make in 2025?

HC Pharma recorded a loss after taxes of € 235,534 in financial year 2025.

What is the revenue of HC Pharma?

As a small company, HC Pharma is not required to publish revenue in its annual accounts. In financial year 2025, its added value was € 968,350.

How much does an employee at HC Pharma earn?

The average wage cost per full-time employee at HC Pharma was € 48,000 in 2025: staff costs of € 791,193 for 16.5 FTE, according to the annual account at the National Bank. That is the employer's cost, not net pay.

How many employees does HC Pharma have?

According to the 2025 annual accounts, HC Pharma has 16.5 full-time equivalents (FTE).

HC Pharma (Private Limited) - Hamme (Vl.) - BE0405023993

Dossier HC Pharma, printed on 29 October 2026 from databakkes.be/en/0405023993/hc-pharma. Sources: CBE, National Bank of Belgium, Belgian Official Gazette.

Warning lights

Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.

Negative equity NBB

More debt than assets in 4 of the last 4 fiscal years.
Two loss years in a row NBB

Negative result in 2024 and 2025.
Tight liquidity NBB

Cash and receivables cover 10 % of short-term debt in 2025; threshold 65 %.
Shrinking team NBB

FTE fell two years in a row, from 24.3 to 16.5.

Financials

Financial year 2025

HC Pharma from Hamme (Vl.), company number BE0405023993, closed financial year 2025 with a result of € -235,534 after tax. For that financial year HC Pharma recorded a gross margin of € 968,350 and equity of € -992,548. Compared with financial year 2024, the result moved from € -16,004 to € -235,534. The company made a loss. More debts than assets. High debts against a small own buffer. The most recent annual accounts were filed with the National Bank of Belgium on May 12, 2026.

What it is worth Caution

€ -992,548

▼ € 235,534 vs 2024

Assets minus debts, by the books. What is left if everything were sold and paid today.

Loss Caution

€ -235,534

▼ 1372 % more loss than in 2024

Profit after tax over the fiscal year.

Cash in the bank

€ 4,220

▼ 6% vs 2024

Cash and bank balances on the last day of the fiscal year.

Where the profit goes Caution

Loss, nothing to pay out

Reserves fell to € -1.6 million.

People and assets in 2025

Full-time equivalents

16.5

▼ 4.7 vs 2024

Average over the fiscal year, from the social balance sheet.

Wage cost

€ 791,193

▼ 8% vs 2024

€ 48,000 per full-time equivalent. Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.

Vehicles and equipment

€ 11,414

▼ 33% vs 2024

Book value of vehicles, furniture and equipment.

Debts at end 2025

Bank debt

None

No bank loans on the last day of the fiscal year.

Owed to suppliers

€ 1.2 million

▲ 267% vs 2024

Supplier invoices still open on the last day of the fiscal year.

Taxes and wages

€ 97,515

▼ 7% vs 2024

Taxes, VAT and social contributions still to pay.

Key figures per fiscal year Download key figures (CSV)
	2022	2023	2024	2025	Change 2024 → 2025
Gross margin	€ 1,171,323 Gross margin 2022: € 1,171,323 First fiscal year in the series	€ 1,241,011 Gross margin 2023: € 1,241,011 ▲ 6% vs 2022 (€ 1,171,323) Favourable step	€ 1,156,890 Gross margin 2024: € 1,156,890 ▼ 7% vs 2023 (€ 1,241,011) Unfavourable step	€ 968,350 Gross margin 2025: € 968,350 ▼ 16% vs 2024 (€ 1,156,890) Unfavourable step	▼ 16%
Profit after taxes	€ 56,560 Profit after taxes 2022: € 56,560 First fiscal year in the series	€ 117,025 Profit after taxes 2023: € 117,025 ▲ 107% vs 2022 (€ 56,560) Favourable step	€ -16,004 Profit after taxes 2024: € -16,004 ▼ € 133,029 vs 2023 (€ 117,025) Unfavourable step	€ -235,534 Profit after taxes 2025: € -235,534 ▼ € 219,530 vs 2024 (€ -16,004) Unfavourable step	▼ € 219,530
Equity	€ -858,035 Equity 2022: € -858,035 First fiscal year in the series	€ -741,010 Equity 2023: € -741,010 ▲ € 117,025 vs 2022 (€ -858,035) Favourable step	€ -757,014 Equity 2024: € -757,014 ▼ € 16,004 vs 2023 (€ -741,010) Unfavourable step	€ -992,548 Equity 2025: € -992,548 ▼ € 235,534 vs 2024 (€ -757,014) Unfavourable step	▼ € 235,534
Total debts	€ 4,644,594 Total debts 2022: € 4,644,594 First fiscal year in the series	€ 4,348,101 Total debts 2023: € 4,348,101 ▼ 6% vs 2022 (€ 4,644,594) Favourable step	€ 5,209,484 Total debts 2024: € 5,209,484 ▲ 20% vs 2023 (€ 4,348,101) Unfavourable step	€ 5,913,816 Total debts 2025: € 5,913,816 ▲ 14% vs 2024 (€ 5,209,484) Unfavourable step	▲ 14%
Cash	€ 8,981 Cash 2022: € 8,981 First fiscal year in the series	€ 3,836 Cash 2023: € 3,836 ▼ 57% vs 2022 (€ 8,981) Unfavourable step	€ 4,481 Cash 2024: € 4,481 ▲ 17% vs 2023 (€ 3,836) Favourable step	€ 4,220 Cash 2025: € 4,220 ▼ 6% vs 2024 (€ 4,481) Unfavourable step	▼ 6%
Land & buildings	€ 2,076,062 Land & buildings 2022: € 2,076,062 First fiscal year in the series	€ 1,979,287 Land & buildings 2023: € 1,979,287 ▼ 5% vs 2022 (€ 2,076,062) Unchanged	€ 1,879,349 Land & buildings 2024: € 1,879,349 ▼ 5% vs 2023 (€ 1,979,287) Unchanged	€ 1,774,796 Land & buildings 2025: € 1,774,796 ▼ 6% vs 2024 (€ 1,879,349) Unchanged	▼ 6%
Retained profit	€ -1,426,635 Retained profit 2022: € -1,426,635 First fiscal year in the series	€ -1,309,610 Retained profit 2023: € -1,309,610 ▲ € 117,025 vs 2022 (€ -1,426,635) Favourable step	€ -1,325,614 Retained profit 2024: € -1,325,614 ▼ € 16,004 vs 2023 (€ -1,309,610) Unfavourable step	€ -1,561,148 Retained profit 2025: € -1,561,148 ▼ € 235,534 vs 2024 (€ -1,325,614) Unfavourable step	▼ € 235,534
Balance sheet total	€ 3,786,559 Balance sheet total 2022: € 3,786,559 First fiscal year in the series	€ 3,607,091 Balance sheet total 2023: € 3,607,091 ▼ 5% vs 2022 (€ 3,786,559) Unchanged	€ 4,452,470 Balance sheet total 2024: € 4,452,470 ▲ 23% vs 2023 (€ 3,607,091) Unchanged	€ 4,921,268 Balance sheet total 2025: € 4,921,268 ▲ 11% vs 2024 (€ 4,452,470) Unchanged	▲ 11%
Employees (FTE)	24.2 Employees (FTE) 2022: 24.2 First fiscal year in the series	24.3 Employees (FTE) 2023: 24.3 ▲ 0.1 vs 2022 (24.2) Unchanged	21.2 Employees (FTE) 2024: 21.2 ▼ 3.1 vs 2023 (24.3) Unchanged	16.5 Employees (FTE) 2025: 16.5 ▼ 4.7 vs 2024 (21.2) Unchanged	▼ 4.7

Key figures of HC Pharma, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.

What happened to HC Pharma?

What happened at HC Pharma in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:

May 12, 2026 New annual accounts for financial year 2025: loss of € 235,534. Source: NBB ↗
2022 Alexo BV became a director. NBB
2022 Louwagie Consulting BV became a director. NBB
2020 Sodiap BV became a director. NBB
Apr 14, 1961 Start of the company according to the CBE. KBO
Mar 1, 1961 New establishment in Hamme (Vl.). KBO

In short

From € 56,560 profit in 2022 to € 235,534 loss in 2025.

Paid € 713 in corporate taxes since 2022.

Best year ever: 2023, with € 117,025 profit.

On average € 58,700 of value added per employee in 2025.

Original PDFs at the National Bank ↗

Management

SODIAP 100%

The stake of SODIAP comes from that shareholder’s own annual accounts; small companies do not report their shareholders themselves.

HC Pharma

Behind HC Pharma are Sodiap BV, Alexo BV and Louwagie Consulting BV. The shares are held by SODIAP (100%).

Directors

According to the 2025 annual accounts

Sodiap BV

Managing director · represented by Tom Goderis

Also active at: SDC, APOTHEEK JENNE, Apotheek de Lisseweg, Apotheek Seurinck, APOTHEEK SCARPHOUT, C.E. FARMA, SANIFAR, WENDUINE PHARMA +24 more

since 2020

Alexo BV

Chairman of the board · represented by Olivier Delaere

Also active at: SDC, SODIAP, APOTHEEK JENNE, PANNOC CHEMIE, Apotheek de Lisseweg, Apotheek Seurinck, APOTHEEK SCARPHOUT, C.E. FARMA +34 more

since 2022

Louwagie Consulting BV

Managing director · represented by Gilles Louwagie

since 2022

Shareholders

SODIAP

100%

Participations

No participations in other companies reported.

Establishments

Establishment units

Physical locations of this company

Registered office

Kapellestraat 55

9220 Hamme (Vl.)

What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.

Details

Company number

0405.023.993

VAT number

BE 0405.023.993

Registered office

Kapellestraat 55, 9220 Hamme (Vl.)

Names & denominations

HC Pharma

Enterprise type

Rechtspersoon

Legal form

Private limited company

Legal situation

Normale toestand

Start date

14 April 1961

Peppol

Active · Active since 6 Jun 2025

Activities · NACE

Detailhandel in farmaceutische producten

Apothekers

View on CBE Public ↗ Annual accounts (NBB) ↗

HC Pharma

Warning lights

Financials

What happened to HC Pharma?

Management

Directors

Shareholders

Participations

Establishments

Establishment units

Details

Frequently asked questions